Incyte Corp., of Wilmington, Del., reported $789.5 million in fourth-quarter revenue. Sales of JAK inhibitor Jakafi (ruxolitinib) increased 11% year over year to $516.9 million. Iclusig (ponatinib) for chronic myeloid leukemia added $28.6 million, up 18% year over year. Recently launched Pemazyre (pemigatinib) for bile duct cancer added $14 million. The rest of the revenue came through royalties from Incyte's partners and milestone payments of $110 million. Incyte recorded $149.9 million in net income, or 68 cents per share, in the fourth quarter, compared to $111 million, or 51 cents per share, in the year-ago quarter. Incyte's management expects 2021 revenue for Jakafi of $2.125 billion to $2.2 billion. Combined net product revenues for the other hematology/oncology products are expected to fall in the $145 million to $160 million range. Shares of Incyte (NASDAQ:INCY) closed Feb. 9 at $89.46, down $4.16.